FDA Brief

Warning letters Drugs

FDA warning letter to

Stokes Healthcare Inc. dba Epicur Pharma

High riskIssued Apr 2, 2024Posted Oct 22, 2024Division of Pharmaceutical Quality Operations I

Sterile compounding facility Epicur Pharma made drugs under insanitary conditions and with serious quality failures, FDA says.

What happened

FDA inspected the Mount Laurel, New Jersey outsourcing facility (a compounder registered under section 503B to make sterile drugs without individual product approvals) from September 26 to October 25, 2023, and issued a Form FDA 483, the list of inspection observations, at the close. Investigators found that drug products meant to be sterile were made under conditions that could contaminate them, including skipped testing of the sterilizing agent for Fluorouracil PF, media fills and airflow (smoke) studies that did not include the riskiest production steps, and disinfectant dwell times shorter than the label requires. FDA also found that the company's quality unit did not investigate a detected trend of Mucor circinelloides mold in three ISO 8 cleanrooms between November 3, 2022 and July 10, 2023, and that lots of Tacrolimus ophthalmic suspension were made and distributed during that period anyway.

What FDA found

  1. Drugs intended to be sterile were prepared, packed or held under insanitary conditions that could contaminate them.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. The quality unit did not investigate a mold (Mucor circinelloides) trend found in cleanrooms C715, C711 and C735 over about eight months, and lots of Tacrolimus AQ exposed to those rooms were still produced and distributed.

    21 CFR 211.192; 21 CFR 211.22(a)
  3. The company did not test the agent used to sterilize Fluorouracil PF, so it has no assurance the sterilization was complete.

    21 CFR 211.113(b)
  4. Media fills, the test runs that show a facility can fill sterile product without contamination, did not include the highest-risk steps such as mixing drug components in large vessels.

    21 CFR 211.113(b)
  5. The sporicidal disinfectant was given less contact time than its label requires, and the required dwell time was not always reached.

    21 CFR 211.42(c)(10)(v)
  6. Labels did not give the quantity or proportion of each inactive ingredient, and containers did not carry MedWatch adverse event reporting information.

    FDCA section 503B(a)(10) [21 U.S.C. § 353b(a)(10)]

What FDA wants

FDA asks the company to write back within 15 working days describing the specific steps taken to fix each violation, with supporting documents, and to explain any delay if the work cannot be finished in that time. FDA also strongly recommends a full assessment of operations, especially aseptic processing, with a third-party consultant who has sterile manufacturing expertise.

Who should pay attention

  • hospitals, surgery centers and clinics that buy compounded sterile drugs such as ophthalmic tacrolimus
  • physicians and patients who receive compounded sterile injections or eye preparations
  • distributors and pharmacies that resell or repackage 503B compounded drugs

This is a summary. Read the original letter on fda.gov.

Stokes Healthcare Inc. dba Epicur Pharma's FDA history

  1. Stokes Healthcare Inc. dba Epicur Pharma

    FDA warned Epicur Pharma over website claims for compounded omeprazole and buprenorphine animal drugs that are false or misleading.

    High risk

Full company page

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk